Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Shield Raises Reduced IPO As Anemia Drug Nears Approval

This article was originally published in Scrip

Executive Summary

Shield Therapeutics, which is expecting EU approval for its novel oral iron replacement drug Feraccru (ST10, ferric maltol) during this quarter, has raised £32.5m in an initial public offering on the AIM market of the London Stock Exchange.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register